Key Takeaways
- Verastem (NASDAQ:VSTM) reached USD 8.29 in the October 14, 2026 morning session, up 11.21%, with 12.044 million shares traded, or 4.0 times average volume. The move coincided with a company investor event scheduled for 8:00 a.m. ET.
- The webcast focused on initial efficacy findings and updated safety information for VS-7375, an oral KRAS G12D ONOFF inhibitor being studied in pancreatic, lung and colorectal cancers. Dr. Manuel Hidalgo Medina of NYU Langone took part.
- Verastem recorded USD 40.1 million in second-quarter revenue, comprising USD 25.1 million of net product revenue and a USD 15.0 million COPIKTRA sales milestone. The company posted a GAAP net loss of USD 34.7 million.
- At June 30, 2026, cash, equivalents and investments totalled USD 136.4 million, or USD 201.4 million on a pro forma basis. Management said that pro forma position supports operations into the second half of 2027.
The Investor Event Coincided With the Price Move
Verastem scheduled its webcast for 8:00 a.m. ET on Wednesday, October 14, 2026, to discuss TARGET-D programme data following a clinical update in June. The timing coincided with an 11.21% gain, but the specific efficacy figures were not verified for this article, so the event cannot be treated as a confirmed explanation for the price change. Shares opened 7.38% higher and gained a further 3.56% from the open. Turnover at four times the average indicated heightened attention around the data presentation. Updates of this type are commonly assessed for response rates, durability and tolerability, while early-stage cohorts can change as enrolment grows; investors also compare results across competing KRAS programmes.
Product Revenue Is Growing, but the Company Still Uses Cash
In results released August 6, 2026, Verastem reported USD 25.1 million of net product revenue from AVMAPKI FAKZYNJA CO-PACK and USD 43.7 million year to date. A USD 15.0 million milestone was triggered after Secura Bio’s cumulative worldwide net sales exceeded USD 200 million. The non-GAAP adjusted net loss was USD 30.6 million, or USD 0.31 per share. The pro forma USD 201.4 million cash figure assumed a USD 50 million royalty financing with Oberland, expected to close on August 28, 2026, as well as the USD 15 million milestone. Royalty financing is linked to future sales and creates a payment obligation. Verastem also markets a combination treatment for low-grade serous ovarian cancer; quarterly product revenue of USD 25.1 million compares with USD 2.1 million a year earlier, illustrating early launch growth.
Clinical Uncertainty and Cash Burn Still Matter
The key risks are immature clinical evidence, competition among KRAS-targeted therapies and continuing cash consumption. Results from a small patient cohort can overstate how well a treatment will perform in broader studies. The company aims to complete enrolment in all three TARGET-D Phase 2 trials by the end of 2026, meet with the FDA before year-end to discuss Phase 3 design, and dose the first patients in 2027. A topline RAMP 301 result is expected in mid-2027. The third-quarter reporting date had not been announced at publication. If additional funding is required for Phase 3 studies, new equity could dilute shareholders, while other oral and injectable KRAS programmes may release competing data. This is not investment advice.
Interpreting the Move Ahead of Clinical Updates
Verastem (NASDAQ:VSTM) rose 11.21% around its October 14, 2026 investor event on VS-7375, although the detailed data were not verified here and no other same-day company announcement was identified. Revenue is increasing and pro forma cash was USD 201.4 million, but the business remained loss-making. The next milestones include an FDA discussion before year-end and the third-quarter report, whose date had not been announced. This is not investment advice.






Please wait processing your request...